Q: What is Uptravi used for?

Uptravi is used to treat pulmonary arterial hypertension .

Q: What are the active ingredients in Uptravi?

The active ingredient in Uptravi is selexipag .

Q: What are the side effects of Uptravi?

Common side effects of Uptravi may include: headache diarrhea jaw pain and others Always consult with a healthcare professional about potential side effects.

Q: What drug class is Uptravi?

Uptravi belongs to the prostacyclin receptor agonist drug class.

Q: Is Uptravi safe during pregnancy and breastfeeding?

Pregnancy It is currently unknown if Uptravi will harm an unborn baby. There are no adequate and well-controlled studies of this medication in pregnant women to determine its safety. While animal studies using high doses did not show evidence of harm to the fetus, animal results do not always predict how a drug will affect humans. This medication should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Breastfeeding It is not known whether Uptravi or its components pass into human breast milk. Because many drugs are excreted in human milk and there is a potential for adverse reactions in nursing infants, healthcare providers typically recommend weighing the benefits of breastfeeding against the potential risks. Some clinical guidance suggests that breastfeeding should be avoided while using this medication. Consult with your doctor to determine the safest course of action for you and your baby.

Q: What forms and strengths does Uptravi come in?

Uptravi is available in the following forms: Oral Tablets: These are film-coated tablets taken by mouth. Intravenous Injection: This is a powder for solution that is reconstituted and administered as an infusion into a vein. The injection is typically used as a temporary replacement for patients who are unable to take the medication orally.

Q: What is the FDA approval status of Uptravi?

FDA Approval History The U.S. Food and Drug Administration (FDA) first approved Uptravi (selexipag) tablets on December 21, 2015. It was introduced as a selective prostacyclin IP receptor agonist for patients with pulmonary arterial hypertension (PAH). In July 2021, the FDA expanded the approval to include an intravenous (IV) formulation. This injection is designed for use in adult patients who are already prescribed Uptravi but are temporarily unable to take the medication by mouth. Approved Indications Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (WHO Group 1) in adults. The regulatory approval is based on its ability to: Delay the progression of the disease. Reduce the risk of hospitalization related to PAH. It may be used as a standalone treatment or in combination with other types of PAH medications, such as endothelin receptor antagonists or phosphodiesterase-5 inhibitors. Regulatory Status Uptravi is available only by prescription. Unlike some other medications used for PAH, Uptravi does not currently require a Risk Evaluation and Mitigation Strategy (REMS) program or carry a Boxed Warning for severe safety risks. It is available in multiple tablet strengths to allow for gradual dose titration.

Question 1

What is Uptravi?

Accepted Answer

Uptravi is a selective prostacyclin receptor agonist that works by mimicking the effects of natural prostacyclin in the body. It targets specific receptors to help relax and widen the blood vessels in the lungs, which improves circulation and reduces the workload on the heart.

By widening these vessels, the medication helps manage high blood pressure within the pulmonary arteries. This process supports better blood flow through the lungs and throughout the rest of the body.

Question 2

What is Uptravi used for?

Accepted Answer

Uptravi is used to treat pulmonary arterial hypertension.

Question 3

How does Uptravi work?

Accepted Answer

Uptravi belongs to a class of medications known as selective prostacyclin receptor agonists. It is designed to act like prostacyclin, a natural compound in the body that helps regulate blood flow in the lungs.

In people with pulmonary arterial hypertension (PAH), the blood vessels in the lungs become narrow and stiff. Uptravi works by targeting and activating specific receptors on the smooth muscle cells of these blood vessels. This activation causes the following effects:

Vasodilation: The blood vessels relax and widen, allowing blood to flow through more easily.
Reduced Pressure: By widening the vessels, the medication lowers the high blood pressure within the pulmonary arteries.
Heart Support: Because the vessels are wider, the right side of the heart does not have to work as hard to pump blood through the lungs.

By improving blood flow and reducing the workload on the heart, Uptravi helps to delay the progression of the disease and reduce the risk of being hospitalized for PAH symptoms.

Question 4

What are the active ingredients in Uptravi?

Accepted Answer

The active ingredient in Uptravi is selexipag.

Question 5

What are the side effects of Uptravi?

Accepted Answer

Common side effects of Uptravi may include:

headache
diarrhea
jaw pain
and others

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Uptravi?

Accepted Answer

Uptravi belongs to the prostacyclin receptor agonist drug class.

Question 7

What is the dosage of Uptravi and how do I take it?

Accepted Answer

Uptravi is available as oral tablets and as an injection for intravenous use. The oral tablets are usually taken twice a day, in the morning and evening. You can take the tablets with or without food, though taking them with food may help you tolerate the medication better.

When taking the tablets:

Swallow the tablets whole.
Do not crush, chew, or break the tablets.

The intravenous form of Uptravi is administered by a healthcare provider. This version is typically used for a short period if you are unable to take the medication by mouth.

Dose Adjustments

Your healthcare provider will likely start you on a low dose and gradually increase it over several weeks. This process helps determine the highest dose you can tolerate. It is important to follow your provider's instructions exactly during this period.

Missed Doses

If you miss a dose of Uptravi, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular schedule. Do not take two doses at once to make up for a missed one.

If you miss your doses for several days in a row, contact your doctor before taking the medication again. Your dose may need to be adjusted or restarted at a lower level.

Question 8

Is Uptravi safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

It is currently unknown if Uptravi will harm an unborn baby. There are no adequate and well-controlled studies of this medication in pregnant women to determine its safety. While animal studies using high doses did not show evidence of harm to the fetus, animal results do not always predict how a drug will affect humans. This medication should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breastfeeding

It is not known whether Uptravi or its components pass into human breast milk. Because many drugs are excreted in human milk and there is a potential for adverse reactions in nursing infants, healthcare providers typically recommend weighing the benefits of breastfeeding against the potential risks. Some clinical guidance suggests that breastfeeding should be avoided while using this medication. Consult with your doctor to determine the safest course of action for you and your baby.

Question 9

What forms and strengths does Uptravi come in?

Accepted Answer

Uptravi is available in the following forms:

Oral Tablets: These are film-coated tablets taken by mouth.
Intravenous Injection: This is a powder for solution that is reconstituted and administered as an infusion into a vein.

The injection is typically used as a temporary replacement for patients who are unable to take the medication orally.

Question 10

What is the FDA approval status of Uptravi?

Accepted Answer

FDA Approval History

The U.S. Food and Drug Administration (FDA) first approved Uptravi (selexipag) tablets on December 21, 2015. It was introduced as a selective prostacyclin IP receptor agonist for patients with pulmonary arterial hypertension (PAH).

In July 2021, the FDA expanded the approval to include an intravenous (IV) formulation. This injection is designed for use in adult patients who are already prescribed Uptravi but are temporarily unable to take the medication by mouth.

Approved Indications

Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (WHO Group 1) in adults. The regulatory approval is based on its ability to:

Delay the progression of the disease.
Reduce the risk of hospitalization related to PAH.

It may be used as a standalone treatment or in combination with other types of PAH medications, such as endothelin receptor antagonists or phosphodiesterase-5 inhibitors.

Regulatory Status

Uptravi is available only by prescription. Unlike some other medications used for PAH, Uptravi does not currently require a Risk Evaluation and Mitigation Strategy (REMS) program or carry a Boxed Warning for severe safety risks. It is available in multiple tablet strengths to allow for gradual dose titration.

Question 11

What should I know about Uptravi and cost?

Accepted Answer

Factors Influencing Cost

Uptravi is a specialty medication used to treat pulmonary arterial hypertension. Because it is a specialty drug, it is often more expensive than standard medications and may require fulfillment through a specialty pharmacy. The total price you pay can be affected by several factors:

Insurance Coverage: Your specific health insurance plan, including your deductible, co-pay, or co-insurance requirements, will significantly impact your out-of-pocket costs.
Dosage and Form: Uptravi is available as oral tablets and as an intravenous injection. The dosage strength and frequency prescribed by your doctor will influence the overall cost.
Pharmacy Choice: Prices may vary between different specialty pharmacies.

Financial Assistance Programs

The manufacturer of Uptravi offers support programs to help eligible patients manage the cost of the medication. These may include:

Savings Cards: Commercially insured patients may be eligible for co-pay cards that reduce out-of-pocket expenses.
Patient Assistance: For patients without insurance or those who are underinsured, the manufacturer may provide the drug at a reduced cost or for free through specific foundation programs.

It is recommended to contact your insurance provider or the manufacturer's support program to get the most accurate estimate of your costs.

Uptravi

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Uptravi

Hospitals.net Disclosure